Acute heart failure : current pharmacological treatment and perspectives
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
Acute heart failure (AHF) represents the most frequent cause of unplanned hospital admission in patients older than 65 years. Symptoms and clinical signs of AHF (e.g. dyspnoea, orthopnoea, oedema, jugular vein distension, and variation of body weight) are mostly related to systemic venous congestion secondary to various mechanisms including extracellular fluids, increased ventricular filling pressures, and/or auto-transfusion of blood from the splanchnic into the pulmonary circulation. Thus, the initial management of AHF patients should be mostly based on decongestive therapies on admission followed, before discharge, by rapid implementation of guideline-directed oral medical therapies for heart failure. The therapeutic management of AHF requires the identification and rapid diagnosis of the disease, the diagnosis of the cause (or triggering factor), the evaluation of severity, the presence of comorbidities, and, finally, the initiation of a rapid treatment. The most recent guidelines from ESC and ACC/AHA/HFSA have provided updated recommendations on AHF management. Recommended pharmacological treatment for AHF includes diuretic therapy aiming to relieve congestion and achieve optimal fluid status, early and rapid initiation of oral therapies before discharge combined with a close follow-up. Non-pharmacological AHF management requires risk stratification in the emergency department and non-invasive ventilation in case of respiratory failure. Vasodilators should be considered as initial therapy in AHF precipitated by hypertension. On the background of recent large randomized clinical trials and international guidelines, this state-of-the-art review describes current pharmacological treatments and potential directions for future research in AHF.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
European heart journal - 44(2023), 44 vom: 21. Nov., Seite 4634-4649 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deniau, Benjamin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute heart failure |
|---|
| Anmerkungen: |
Date Completed 22.11.2023 Date Revised 22.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/eurheartj/ehad617 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363431977 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363431977 | ||
| 003 | DE-627 | ||
| 005 | 20231226093332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/eurheartj/ehad617 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1211.xml |
| 035 | |a (DE-627)NLM363431977 | ||
| 035 | |a (NLM)37850661 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deniau, Benjamin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Acute heart failure |b current pharmacological treatment and perspectives |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.11.2023 | ||
| 500 | |a Date Revised 22.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a Acute heart failure (AHF) represents the most frequent cause of unplanned hospital admission in patients older than 65 years. Symptoms and clinical signs of AHF (e.g. dyspnoea, orthopnoea, oedema, jugular vein distension, and variation of body weight) are mostly related to systemic venous congestion secondary to various mechanisms including extracellular fluids, increased ventricular filling pressures, and/or auto-transfusion of blood from the splanchnic into the pulmonary circulation. Thus, the initial management of AHF patients should be mostly based on decongestive therapies on admission followed, before discharge, by rapid implementation of guideline-directed oral medical therapies for heart failure. The therapeutic management of AHF requires the identification and rapid diagnosis of the disease, the diagnosis of the cause (or triggering factor), the evaluation of severity, the presence of comorbidities, and, finally, the initiation of a rapid treatment. The most recent guidelines from ESC and ACC/AHA/HFSA have provided updated recommendations on AHF management. Recommended pharmacological treatment for AHF includes diuretic therapy aiming to relieve congestion and achieve optimal fluid status, early and rapid initiation of oral therapies before discharge combined with a close follow-up. Non-pharmacological AHF management requires risk stratification in the emergency department and non-invasive ventilation in case of respiratory failure. Vasodilators should be considered as initial therapy in AHF precipitated by hypertension. On the background of recent large randomized clinical trials and international guidelines, this state-of-the-art review describes current pharmacological treatments and potential directions for future research in AHF | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute heart failure | |
| 650 | 4 | |a Assessment of congestion | |
| 650 | 4 | |a Decongestion therapy | |
| 650 | 4 | |a Guideline-directed medical therapy | |
| 650 | 4 | |a Non-invasive ventilation | |
| 700 | 1 | |a Costanzo, Maria Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Sliwa, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Asakage, Ayu |e verfasserin |4 aut | |
| 700 | 1 | |a Mullens, Wilfried |e verfasserin |4 aut | |
| 700 | 1 | |a Mebazaa, Alexandre |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European heart journal |d 1983 |g 44(2023), 44 vom: 21. Nov., Seite 4634-4649 |w (DE-627)NLM012617253 |x 1522-9645 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2023 |g number:44 |g day:21 |g month:11 |g pages:4634-4649 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/eurheartj/ehad617 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2023 |e 44 |b 21 |c 11 |h 4634-4649 | ||